Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473888 | 0.92 | KDM4E (0.35) | KDM4EKMT2AL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL5086304 | 0.85 | ALDH1A1 (0.34) | KDM4EKMT2AALDH1A1GAATDP1 | |
| SCHEMBL4464838 | 0.79 | ALDH1A1 (0.38) | KDM4EL3MBTL1ALDH1A1RAB9ATDP1 | |
| SCHEMBL4465143 | 0.76 | ALOX5 (0.33) | NPC1RAB9ASMN1; SMN2TLR8CNR1 | |
| SCHEMBL6380921 | 0.74 | PTPN1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL2125548 | 0.69 | ALDH1A1 (0.46) | KDM4EKMT2AL3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL4470044 | 0.68 | GSTP1 (0.35) | CYP1A2CYP2D6CYP2C19HTR2ACNR2 | |
| SCHEMBL18650205 | 0.67 | ATM (0.41) | KDM4EKMT2AL3MBTL1ALDH1A1GAA | |
| SCHEMBL22288166 | 0.66 | MAPT (0.39) | KDM4EKMT2AL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL27478496 | 0.66 | PPARG (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569651-B2 | Transition metal compound, ligand system, catalyst system and its use for the polymerization and copolymerization of olefins | BASELL POLYPROPYLEN GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7342078-B2 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | BASELL POLYOLEFINE GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-20060020096-A1 | Transition metal compound, ligand system, catalyst system and its use for the polymerization and copolymerization of olefins | SCHOTTEK JORG | 2006-01-26 | — | — | US | disclosed |
| US-20030149199-A1 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | BASELL POLYPROPYLEN GMBH (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149199-A1 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | PORCN, PGR, PPOX | KDM4E 3968/4885KMT2A 2666/4885L3MBTL1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.